Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Analysis Report 2026

Report Coverage

The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into adeno-associated virus (AAV) vectors in gene therapy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for adeno-associated virus (AAV) vectors in gene therapy. The adeno-associated virus (AAV) vectors in gene therapy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The adeno-associated virus (AAV) vectors in gene therapy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with adeno-associated virus (AAV) vectors in gene therapy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to adeno-associated virus (AAV) vectors in gene therapy.

Read more about this report - Request a Free Sample

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Outlook

Adeno-associated virus (AAV) vectors in gene therapy are engineered viral delivery systems used to transfer therapeutic genes into targeted cells for the treatment of genetic and rare disorders. These vectors provide efficient gene expression, low immunogenicity, and long-term therapeutic potential. Advancements in AAV capsid engineering, AAV tropism and tissue targeting, and durability of AAV transgene expression have improved the development of targeted therapies across neurological, muscular, ocular, and hepatic diseases using different AAV serotypes (AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh10).

Adeno-associated virus vector-based gene therapy treatment involves the delivery of functional genetic material into affected cells to replace, repair, or modify defective genes responsible for inherited disorders. The therapy supports targeted and long-lasting gene expression while advancing precision medicine applications in rare and chronic diseases. In April 2026, the United States Food and Drug Administration approved Otarmeni (lunsotogene parvec-cwha), a dual adeno-associated virus serotype 1 (AAV1)-based gene therapy for Otoferlin (OTOF) gene-associated severe-to-profound hearing loss. The therapy demonstrated significant hearing restoration benefits, highlighting advancements in AAV manufacturing and scale-up, single-dose gene therapy economics, and innovative gene delivery technologies in the Adeno-Associated Virus vectors in gene therapy market pipeline.

Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Pipeline Therapeutic Assessment

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, at 39%, covers a major share of the total adeno-associated virus (AAV) vectors in gene therapy clinical trials, reflecting strong mid-stage clinical advancement and expanding therapeutic potential in the gene therapy market. Phase I accounts for 37%, supported by increasing early-stage innovation and safety evaluations. Phase III represents 18%, indicating growing commercialization opportunities. Early phase I contributes 6%, highlighting continuous pipeline expansion and future market development potential.

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the adeno-associated virus (AAV) vectors in gene therapy pipeline analysis include small molecules, oligonucleotides, and peptides. The adeno-associated virus (AAV) vectors in gene therapy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for adeno-associated virus (AAV) vectors in gene therapy. Adeno-associated virus vector-based molecules are increasingly being investigated in the gene therapy pipeline owing to their high transduction efficiency and long-term gene expression capabilities. For instance, NG101, an investigational adeno-associated virus vector gene therapy developed by Neuracle Genetics, is being evaluated for wet age-related macular degeneration. Additionally, recombinant adeno-associated virus vectors are under development for neurological, retinal, and rare inherited disorders to improve targeted therapeutic delivery and clinical efficacy.

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Clinical Trials – Key Players

The EMR report for the adeno-associated virus (AAV) vectors in gene therapy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides detailed adeno-associated virus (AAV) vectors in gene therapy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in adeno-associated virus (AAV) vectors in gene therapy clinical trials:

• Ultragenyx Pharmaceutical Inc.
• Aspa Therapeutics
• Rocket Pharmaceuticals Inc.
• Elisigen, Inc.
• ORA, Inc.
• Unlimited Biotechnology LLC
• Adrenas Therapeutics Inc.
• BioMarin Pharmaceutical
• Beacon Therapeutics
• GeneCradle Inc.
• Spark Therapeutics, Inc.
• UniQure Biopharma B.V.

Adeno-Associated Virus (AAV) Vectors in Gene Therapy – Emerging Drugs Profile

Key Questions Answered in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Insight Report

• Which companies/institutions are leading the adeno-associated virus (AAV) vectors in gene therapy drug development?
• Which company is leading the adeno-associated virus (AAV) vectors in gene therapy pipeline development activities?
• What is the current adeno-associated virus (AAV) vectors in gene therapy commercial assessment?
• What are the opportunities and challenges present in the adeno-associated virus (AAV) vectors in gene therapy pipeline landscape?
• What is the efficacy and safety profile of adeno-associated virus (AAV) vectors in gene therapy pipeline drugs?
• Which company is conducting major trials for adeno-associated virus (AAV) vectors in gene therapy drugs?
• Which companies/institutions are involved in adeno-associated virus (AAV) vectors in gene therapy collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Adeno-Associated Virus (AAV) Vectors in Gene Therapy?

Reasons To Buy This Report

The Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for adeno-associated virus (AAV) vectors in gene therapy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into adeno-associated virus (AAV) vectors in gene therapy collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Adeno-Associated Virus Vector-Based Gene Therapy Market